



Effective Date 5/15/2025

Coverage Policy Number IP0314

Finerenone

Table of Contents

Overview	1
Medical Necessity Criteria	1
Reauthorization Criteria	2
Authorization Duration	2
Conditions Not Covered.....	2
Background.....	3
References	4
Revision Details	4

Related Coverage Resources

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for finerenone (Kerendia®) tablets.

Medical Necessity Criteria

Finerenone (Kerendia) is considered medically necessary when the following are met:

1. **Diabetic Kidney Disease.** Individual meets **ALL** of the following criteria (A, B, C, D and E):
 - A. Age 18 years of age or older
 - B. Has chronic kidney disease (CKD) associated with type 2 diabetes
 - C. Meets **ONE** of the following (i or ii):

- i. Is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
- ii. According to the prescriber, has a contraindication to ACE inhibitor and ARB therapy
- D. At baseline (prior to the initiation of Kerendia), individual meets **ALL** of the following (i, ii, and iii):
 - i. Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m²
 - ii. Urine albumin-to-creatinine ratio ≥ 30 mg/g
 - iii. Serum potassium level ≤ 5.0 mEq/L
- E. Preferred product criteria is met for the product as listed in the below table

Individual and Family Plans:

Product	Criteria
Kerendia (Finerenone)	<p>Patient has tried, or is currently taking, ONE of the following (A <u>or</u> B):</p> <ul style="list-style-type: none"> A. Farxiga B. Jardiance <p><u>Note:</u> A trial of, or if the patient is currently taking, another SGLT-2 inhibitor or SGLT-2 inhibitor-containing combination product also satisfies this requirement.</p> <p><u>Note:</u> Examples of SGLT-2 inhibitors include Farxiga, Invokana, Jardiance, Steglatro. Examples of SGLT-2 combination products include Invokamet, Invokamet XR, Qtern, Segluromet, Synjardy, Synjardy XR, Xigduo XR.</p>

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Reauthorization Criteria

Continuation of finerenone (Kerendia) is considered medically necessary for diabetic kidney disease when the above medical necessity criteria are met AND there is documentation of beneficial response.

Authorization Duration

Initial approval duration is up to 12 months.

Reauthorization approval duration is up to 12 months.

Conditions Not Covered

Any other use is considered experimental, investigational or unproven including the following (this list may not be all inclusive):

1. **Heart Failure (Treatment).** Patients with a clinical diagnosis of heart failure with reduced ejection fraction (New York Heart Association [NYHA] class II through IV) were excluded from FIDELIO-DKD and FIGARO-DKD.^{2,3} Kerendia was compared with eplerenone in the Phase IIb ARTS-HF trial (n = 1,066) among patients with heart failure with reduced ejection fraction and type 2 diabetes and/or chronic kidney disease.⁵ The primary endpoint was proportion of patients with > 30% decline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at Day 90. Kerendia induced a > 30% decrease in NT-proBNP levels in a similar proportion of patients compared with eplerenone. Further data are needed to characterize the role of Kerendia in chronic heart failure management. In an update to American College of Cardiology heart failure guidelines (2021), aldosterone antagonists (spironolactone, eplerenone) are recognized as add-on therapy to ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors for patients with NYHA class II through IV symptoms

meeting renal and serum potassium criteria (class I recommendation).⁶ Kerendia is not addressed in heart failure guidelines.

2. **Hypertension (Treatment).** Kerendia has not been evaluated for use in essential hypertension and is not mentioned in American College of Cardiology/American Heart Association hypertension guidelines (2017).⁷ Spironolactone and eplerenone are cited as secondary agents for management of hypertension and are noted to be common add-on therapies for resistant hypertension. Primary agents include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers.
3. **Concomitant Use with Spironolactone or Eplerenone.** Spironolactone and eplerenone are steroidal mineralocorticoid receptor antagonists. Based on their mechanism of action, an increase in adverse events (e.g., hyperkalemia) would be expected if used concomitantly with Kerendia. Concomitant spironolactone or eplerenone use was not permitted in clinical trials.

Background

OVERVIEW

Kerendia, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is indicated in adults with **chronic kidney disease (CKD) associated with type 2 diabetes** to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular (CV) death, non-fatal myocardial infarction, and hospitalization for heart failure.¹

Per the prescribing information, do not initiate treatment with Kerendia if serum potassium is > 5.0 mEq/L.¹ Additionally, initiation of Kerendia is not recommended in patients with $\text{eGFR} < 25$ mL/min/1.73 m². Kerendia labeling includes a Warning regarding hyperkalemia and notes that the risk increases with decreasing kidney function. Monitoring of serum potassium and eGFR is recommended.

Clinical Efficacy

Efficacy of Kerendia was evaluated in two published Phase III, placebo-controlled trials, FIDELIO-DKD (n = 5,734) and FIGARO-DKD (n = 7,352).^{2,8} All patients were required to be treated with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at the maximum tolerated labeled dose for ≥ 4 weeks prior to the run-in visit. Additionally, patients were required to have a urinary albumin-to-creatinine ratio of ≥ 30 mg/g, in addition to other renal entry criteria.

Guidelines

The American Diabetes Association (ADA) Standards of Care (2024) recommend Kerendia for patients with type 2 diabetes and CKD with albuminuria treated with maximum tolerated doses of ACE inhibitors or ARBs, to improve CV outcomes and reduce the risk of CKD progression (level A recommendation).³ In individuals with type 2 diabetes and diabetic kidney disease, Kerendia is recommended to reduce the risk of hospitalization for heart failure (level A recommendation).

Additionally, in the section regarding CKD (Chapter 11), it is noted that in patients with diabetic kidney disease and type 2 diabetes, use of sodium glucose co-transporter-2 inhibitors (if eGFR is ≥ 20 mL/min/1.73 m²), a glucagon-like peptide-1 agonist, or Kerendia (if eGFR is ≥ 25 mL/min/1.73 m²), should be considered for CV risk reduction (level A recommendation). In patients with CKD and albuminuria, who are at increased risk for CV events or CKD progression, Kerendia is recommended to reduce CKD progression and CV events (level A recommendation).

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in CKD (2022) suggests use of Kerendia in patients with type 2 diabetes with $\text{eGFR} \geq 25$ mL/min/1.73 m², normal serum potassium, and albuminuria (≥ 30 mg/g) despite maximal tolerated doses of a renin-angiotensin-aldosterone system (RAAS) inhibitor.⁴ The rationale for adding an MRA to current standard of care, including ACE inhibitor or ARB, is that this combination has been proven to be an effective strategy to reduce albuminuria in patients with diabetes and CKD. The steroidal MRAs, spironolactone and eplerenone, have been shown to effectively reduce albuminuria; however, there are no data demonstrating that these agents reduce the risk of clinical outcomes. Kerendia reduces albuminuria and the risk of kidney and CV outcomes. The guidelines also note that Kerendia is

most appropriate for patients with type 2 diabetes who are at high risk of CKD progression and CV events, because Kerendia can be added to an ACE/ARB and a sodium glucose co-transporter-2 inhibitor for treatment of type 2 diabetes and CKD.

A consensus report from the ADA/KDIGO (2022) for diabetes management in CKD states that Kerendia is recommended for patients with type 2 diabetes, eGFR ≥ 25 mL/min/1.73 m², normal serum potassium concentration, and albuminuria (albumin:creatinine ratio ≥ 30 g/g) despite a maximum tolerated dose of RAAS inhibitor therapy.¹⁰

References

1. Kerendia® tablets [prescribing information]. Whippany, NJ: Bayer; September 2022.
2. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383(23):2219-2229.
3. American Diabetes Association. Standards of care in diabetes – 2024. *Diabetes Care*. 2024;47(Suppl 1):S1-S321.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: Rossing P, Muiza Caramori M, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*. 2022;102(5S):S1-S127.
5. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. *Eur Heart J*. 2016;37(27):2105-14.
6. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895-e1032.
7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6):e13-e115.
8. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med*. 2021;385(24):2252-2263.
9. Kittleson MM, Panjath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2023;81(18):1835-1878.
10. Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2022;102:974-989.
11. McDonagh TA, Metra M, Adamo M, et al; European Society of Cardiology (ESC) Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2023;44(37):3627-3639.

Revision Details

Type of Revision	Summary of Changes	Date
Selected Revision	<p>Diabetic Kidney Disease.</p> <p>Added “Meets ONE of the following (a <u>or</u> b): a. Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); b. According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy”</p> <p>Added “At baseline (prior to the initiation of Kerendia), individual meets ALL of the following (a, b, <u>and</u> c): a. Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m²; b.</p>	12/1/2024

	Urine albumin-to-creatinine ratio \geq 30 mg/g; c. Serum potassium level \leq 5.0 mEq/L” Added preferred product requirement criteria for Individual and Family Plans	
Selected Revision	Preferred Product Table – Individual and Family Plans: Updated from “Documented failure, contraindication, or intolerance to ONE of the following (A or B):” to “Patient has tried, or is currently taking ONE of the following (A or B):” Updated note from “A trial of another SGLT-2 inhibitor or SGLT-2 inhibitor-containing combination product also satisfies this requirement” to “A trial of, or if the patient is currently taking another SGLT-2 inhibitor or SGLT-2 inhibitor-containing combination product also satisfies this requirement.”	5/15/2025

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.